Jason Mugg, SVP, Emerging Businesses, AARP

Jason Mugg leads AARP Services Emerging Businesses department. He leads the company’s efforts in Business Development, Innovation, and Corporate Development. He was instrumental in standing up AARP’s Brain Health Fund that invested $60 million dollars in the fight to find a cure for Alzheimer’s and dementia. Previous to this role he led Data Analytics & Performance Management for the past ten years within AARP. Before joining AARP, he worked for America Online and XO Communications. Jason played NCAA division I soccer as a scholarship athlete for the University of New Hampshire and is also an alumnus of Harvard Business School earning his General Management degree in 2014. He lives with his wife and two children in Arlington, Virginia.

Sarah Lenz Lock, Senior Vice President for Policy and Brain Health, AARP’s Policy, Research and International (PRI)

Sarah Lenz Lock is Senior Vice President for Policy and Brain Health in AARP’s Policy, Research and International (PRI). Ms. Lock leads AARP’s policy initiatives on brain health and care for people living with dementia, including serving as the Executive Director of the Global Council on Brain Health, an independent collaborative of scientists, doctors, and policy experts convened by AARP to provide trusted information on brain health. Previously, Ms. Lock was Senior Attorney/Manager at AARP Foundation Litigation conducting health care impact litigation on behalf of older persons. Ms. Lock has been a Trial Attorney for the U.S. Department of Justice, a Legislative Assistant in the U.S. House of Representatives to Congressman Michael D. Barnes working with the Federal Government Service Task Force, and also worked at the law firm of Arent, Fox, Kintner, Plotkin & Kahn.

Maria C. Carillo, PH.D., Chief Science Officer, Alzheimer's Association

As chief science officer, Maria C. Carrillo, Ph.D., sets the strategic vision for the Alzheimer’s Association global research program. Under her leadership, the Association is the world’s largest nonprofit funder of Alzheimer’s research — investing more than $455 million since 1982 — and an internationally recognized pioneer in convening the dementia science community. Dr. Carrillo uses her platform as a noted public speaker to play an instrumental role in the Association’s efforts to lobby for increased funding for the disease.

Dr. Carrillo oversees the implementation of the Association’s growing portfolio of research initiatives, including the Alzheimer’s Association International Conference® (AAIC®), the world’s largest and most influential dementia science meeting, and the Research Roundtable, which enables international scientific, industry and government leaders to work together to overcome shared obstacles in Alzheimer’s science and drug development. In addition, she leads the Association’s direct involvement in research by serving as a co-primary investigator for the Association-funded and led U.S. POINTER study, a lifestyle intervention trial to prevent cognitive decline and dementia.

Dr. Carrillo earned her Ph.D. from Northwestern University’s Institute for Neuroscience and completed a postdoctoral fellowship focused on Alzheimer’s brain imaging and risk factors at Rush University Medical Center in Chicago.

Heather M. Snyder, Ph.D., Vice President of Medical and Scientific Relations, Alzheimer's Association

Dr. Snyder is the vice president of Medical and Scientific Relations at the Alzheimer’s Association. In this role, she oversees Association initiatives that accelerate innovative Alzheimer’s research and provide opportunities for the global dementia community to connect and collaborate. Dr. Snyder is responsible for the progress the Association has made in Alzheimer's and dementia research funding. She leads the Association’s International Research Grant Program, the vehicle through which the Association funds promising investigations that advance understanding of Alzheimer's and moves the field toward solutions for the global Alzheimer's crisis. As the world’s largest nonprofit funder of Alzheimer's research, the Association is currently investing over $208 million in 590 active best-of-field projects in 31 countries. She holds a Ph.D. in molecular biology from Loyola University Chicago Stritch School of Medicine and a bachelor's degree in biology and religious studies from the University of Virginia.

Rafael C Jimenez, Head of the Research Informatics team at Alzheimer's Research UK & Operations Director, Early Detection of Neurodegenerative Diseases initiative (EDoN)

Rafael C Jimenez is the Head of the Research Informatics team at Alzheimer's Research UK and the Operations Director of the Early Detection of Neurodegenerative Diseases initiative (EDoN). He and his team lead the coordination and support the implementation of data science projects focused on digital biomarkers for detecting and diagnosing diseases which cause dementia. He has extensive experience leading data management and data integration efforts especially designing and implementing strategies and data services in the areas of genomics, proteomics, neurobiology, and bioinformatics. For 5 years he was the CTO and Chief Data Architect of ELIXIR contributing to building the data infrastructure of major initiatives like ELIXIR, EMBL-EBI and EOSC. He did also lead and establish major community efforts like BioJS, Bioschemas and Biocontainers and was a major contributor to the development of data standards and data federated frameworks under the umbrella of initiatives like HUPO-PSI. As part of EMBL-EBI he also led the development of data resources and bioinformatics solutions contributing to building well-known proteomics data resources like IntAct and UniProt.

Ian Wilson, Deputy CEO & Executive Director of Fundraising & Communications, Alzheimer’s Research UK (ARUK)

Ian is Deputy CEO and Executive Director of Fundraising & Communications at Alzheimer’s Research UK (ARUK). Ian joined ARUK in September 2013 and is responsible for leading their fundraising, public engagement, marketing, and communications activities. Ian also has overarching responsibility for their Early Detection of Neurodegenerative Diseases initiative (EDoN) and is a Board member of the UK Dementia Research Institute (UK DRI). Prior to this appointment, Ian was at Cancer Research UK with responsibility for delivering funding towards a number of multi-million pound projects within the organisation.

Samantha Budd Haeberlein, Ph.D., Senior Vice President, Head, Neurodegeneration Development Unit, Biogen

Samantha Budd Haeberlein has twenty years of biopharmaceutical industry experience across Research, Translational Medicine and Clinical Development. Based in Cambridge, MA Samantha currently leads the Neurodegeneration Development Unit accountable for the Clinical Development of Biogen’s Alzheimer’s disease, dementia & Movement Disorders portfolios. Prior to Biogen Samantha was at AstraZeneca where she held roles in the US, Canada and Sweden as Vice President of Translational Science & Global Program Lead in Alzheimer’s disease.

Samantha is a member of the World Dementia Council, and an executive member of the Board of The Boston Home. Samantha has a BSc and a Ph.D. in Biochemistry from the University of Dundee in Scotland. She was an Instructor at Harvard Medical School, Boston and conducted research at The Burnham Institute in San Diego before joining the biopharmaceutical industry.

Stacie Weninger, President of FBRI

Stacie Weninger is the President of FBRI. Prior to this position, she was the Senior Director of Science Programs for the Fidelity Foundations. In 2005, Dr. Weninger served as the Project Manager and Senior Analyst for the Task Force on Women in Science at Harvard University. From 2001-2005, Dr. Weninger was a Senior Scientist at Cell Press for the journal Neuron. Before joining Cell Press, Dr. Weninger was a postdoctoral research fellow at Children’s Hospital Boston and Harvard Medical School with Dr. Bruce Yankner. She was a Howard Hughes Medical Institute predoctoral fellow in the Program in Neuroscience at Harvard University. While a graduate student and postdoctoral research fellow, Dr. Weninger was actively involved in undergraduate teaching, winning six teaching awards.

Dr. Weninger received a Ph.D. in neuroscience from Harvard University, and a B.S. degree in chemistry with highest honors from the University of North Carolina, Chapel Hill. She currently chairs the Collaboration for Alzheimer’s Prevention; is President of Alzforum; serves as Chairman of the Board of Directors for Rugen Therapeutics; serves as a member of the Board of Directors for Aratome, Atalanta, Eikonizo, RBNC, Sironax, and Target ALS; and serves as a member of the Scientific Advisory Boards for the Indian Institute of Science’s Centre for Brain Research and the UK Dementia Research Institute. She is also a member of Pfizer’s Genetics Scientific Advisory Panel. She previously served as a founding member of the Board of Directors for Denali Therapeutics (NASDAQ: DNLI); as well as a member of the Board of Directors for Abelian (acquired by RBNC), Annexon Biosciences (NASDAQ: ANNX), BRI-Alzan (acquired by MeiraGTx), Digital Cognition Technologies (acquired by Linus Health), Enspectra, Inscopix, Syllable Life Sciences (acquired by RBNC), and Q-State Biosciences.

Niranjan Bose, Managing Director (Health & Life Sciences Strategy) at Gates Ventures

Niranjan Bose is currently the Managing Director (Health & Life Sciences Strategy) at Gates Ventures LLC, where he serves as the Science Advisor to Mr. Bill Gates. Prior to joining Gates Ventures in August 2014, he was the Chief of Staff to the President of the Global Health Program at the Bill & Melinda Gates Foundation.

He was with the Gates Foundation from 2007 through 2014, which included a few years with their Enterics and Diarrheal Diseases (EDD) program strategy team, where he was responsible for managing a portfolio of investments, which included clinical development of enteric vaccines (rotavirus, cholera, enterotoxigenic E coli and shigella).

Prior to joining the Bill & Melinda Gates Foundation, he was with Strategic Decisions Group (and SDG Life Sciences), where he was a Senior Consultant and assisted clients in the pharmaceutical and biotechnology industries with strategy development, company valuations, portfolio management frameworks, revenue forecasting, and competitive assessments.

Niranjan holds a Ph.D. in biochemistry from Dartmouth College and an MS in biological sciences and BS in pharmaceutical sciences from Birla Institute of Technology and Science, Pilani, India. He also received the Business Bridge Diploma from the Tuck School of Business at Dartmouth.

Jonah Goldman, Managing Director, Advocacy & Government Relations – Gates Ventures

Jonah joined Gates Ventures, Bill Gates’s private office, in September 2014. He is responsible for the organization’s relationships with policymakers around the world. In 2015, he worked with Bill to establish the Breakthrough Energy Coalition (BEC) – a group of individuals and institutions committed to investing significant capital in energy innovations that do not contribute to climate change. As part of that effort, Jonah worked with the United States, France, India, and more than 15 other countries to establish Mission Innovation, which committed to double the government supported R&D into these technologies. In 2016, he worked with a group of members of the BEC to establish Breakthrough Energy Ventures (BEV), a fund focused on executing the vision of the Breakthrough Energy Coalition. He serves as a Senior Advisor to BEV.

Prior to Gates Ventures, Jonah worked on the communications team at the Bill & Melinda Gates Foundation. Before that, he spent nearly 15 years in Washington, D.C., leading integrated advocacy, communications, and grassroots campaigns. He led a series of campaigns to affect policy on a variety of issues – from civil rights to education reform to nuclear non-proliferation. Before that, he served as primary spokesperson and chief strategist for the largest national campaign to protect voting rights.

Jonah holds a J.D. degree from Boston College Law School and a B.A. degree in History from Binghamton University.

Dr. Rob Buckle, Chief Science Officer, Medical Research Council (UKRI Head Office, London, UK)

Dr. Rob Buckle is Chief Science Officer at the Medical Research Council (MRC), which is part of UK Research and Innovation (UKRI) and the main Government agency responsible for UK biomedical research. MRC invests ~£800m per year on world-class research across the biomedical spectrum with the mission to improve human health and enhance the economic competitiveness of the UK.

As CSO, Rob oversees MRC’s scientific operations and funding procedures, major science initiatives and research implementation programmes. He also provides leadership for MRC in developing networks and inter-organisational relationships, both nationally and internationally.

In relation to dementias research, Rob has been a major contributor to the development of the UK Government’s strategic approach to this area, and played a key role in the establishment of the £250m UK Dementia Research Institute and the MRC Dementias Platform UK. At the international level Rob has served as a founder member on the Executive Boards for both the EU’s Joint Programming Initiative in Neurodegeneration (JPND) and the Centres of Excellence in Neurodegeneration (COEN) initiative. He also chaired the OECD working group on big data in dementia research between 2014 and 2015.

Dr. Claire Newland, Head of Data Science, Medical Research Council (UKRI Head Office, London, UK)

Dr Claire Newland is Head of Data Science at the UK Medical Research Council (MRC), which is the main Government agency responsible for UK biomedical research, and is part of UKRI (UK Research and Innovation).

Claire joined the MRC in 2000, and has had responsibility for a wide range of biomedical research and innovation portfolios in that time, including stratified medicine and experimental medicine, large scale genetic and genomic activities and population cohorts (e.g. UK Biobank), global health particularly infectious diseases, cancer research, clinical trials (largely phase III), health services research and primary care, ageing research, and clinical neurology and imaging. After obtaining a PhD at University College London in 1990, Claire had a 10-year career as a neuroscientist, with posts at University of Washington (Seattle, USA) and Oxford University.

Richard J. Hodes, M.D., Director, National Institute on Aging, NIH ex officio

Richard J. Hodes, M.D., has directed the National Institute on Aging (NIA) at the National Institutes of Health since 1993. Under Dr. Hodes’ stewardship, the NIA budget has grown to over $3.5 billion, reflecting increased public interest in aging as America and the world grow older. Dr. Hodes has devoted his tenure to the development of a strong, diverse, and balanced research program, focusing on the genetics and biology of aging, basic and clinical studies aimed at reducing disease and disability, including Alzheimer’s disease and related dementias; age-related cognitive change; and investigations of the behavioral and social aspects of aging.

Dr. Hodes is a graduate of Yale University and received his M.D. from Harvard Medical School. He completed training in Internal Medicine at Massachusetts General Hospital and in Oncology at the National Cancer Institute. He is an influential scientist in and contributor to the field of immunology, having authored more than 250 research papers.

Eliezer Masliah, M.D., Director, Division of Neurosciences, NIA/NIH ex officio

Dr. Masliah joined the NIA/NIH as Director of the Division of Neurosciences in the summer of 2016. Dr. Masliah received his M.D. from the National Autonomous University of Mexico in 1982. He completed a postgraduate residency training in pathology at the National Institutes of Health in Mexico City in 1986. Following a fellowship in neuropathology and neurodegenerative disorders at the University of California, San Diego (UCSD), before joining NIA he held joint appointments as tenured track Professor at the Departments of Neurosciences and Pathology and as Director of the Autopsy Service at UCSD-Medical Center.

As head of UCSD’s Experimental Neuropathology Laboratory, he investigated synaptic damage in neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, dementia with Lewy bodies, multiple system atrophy and AIDS-related dementia. His laboratory was involved with the discovery of a-synuclein and developed novel models of neurodegeneration as well as new gene therapies, small molecules and experimental immunotherapies for Alzheimer's disease and Parkinson's disease. Four of the experimental therapeutic approaches developed at his laboratory targeting a-synuclein have now passed Phase I clinical trials. He also directed the neuropathology core of the NIA-supported Shirley-Marcos Alzheimer’s Disease Research Center.

A prolific author with approximately 800 original research articles, 70 book chapters and dozens of patents, Dr. Masliah has familiarity with NIA as a past member of the NIA National Advisory Council on Aging, the NIA Neuroscience of Aging Study Section, and the Cellular and Molecular Biology of Neurodegeneration Study Section. He has also served as an advisor in the expert panels to revise the criteria for the neuropathological diagnosis of Alzheimer’s Disease organized by the NIA and the Alzheimer’s Association, at expert meetings and workshops to advise in the use of preclinical models for Alzheimer’s Disease and at a series of NIH-hosted Summits on Alzheimer’s and related dementias. Masliah served as a member of the Scientific Advisory Board of the Alzheimer’s Association from 2010-2016”.

As Director of the Division of Neurosciences at NIA, Dr. Masliah is responsible for managing the portfolios and providing leadership on NIH sponsored programs dedicated at better understanding brain aging and Alzheimer’s Disease, the Division plays a key role in developing the implementation research milestones targeting the ultimate goal of the National Plan to Address Alzheimer’s Disease, which calls for the nation to identify effective ways to treat or prevent Alzheimer’s disease and related dementias by 2025. Dr. Masliah also participates at the NIA Intramural program as investigator in the Laboratory of Neurogenetics.

Paul Ramsey, M.D., CEO of UW Medicine, Executive Vice President for Medical Affairs and Dean of the UW School of Medicine

Paul Ramsey, M.D., is CEO of UW Medicine, executive vice president for Medical Affairs and Dean of the UW School of Medicine with executive responsibility for three hospitals (University of Washington Medical Center, Harborview Medical Center and Valley Medical Center), the University of Washington School of Medicine, the largest physician practice plan in the northwest---UW Physicians, UW Neighborhood Clinics, and Airlift Northwest.

Dr. Ramsey’s research has focused on assessing physicians’ clinical competence. Dr. Ramsey earned his M.D. from Harvard. He is board certified in both Infectious Disease and Internal Medicine. He was the first holder of the Robert G. Petersdorf Endowed Chair in Medicine. He served as a Henry J. Kaiser Family Foundation Faculty Scholar in General Internal Medicine. He has received the Distinguished Teacher Award and the Margaret Anderson Award from UW Medicine’s graduating class. He received the John P. Hubbard Award from the National Board of Medical Examiners. He has served on many national committees and is a member of multiple organizations including the Association of American Physicians and the Institute of Medicine of the National Academy of Sciences.

Dr Georgina MacKenzie, Portfolio Manager, Neuroscience and Mental Health, Wellcome Trust

Dr Georgina MacKenzie is a Portfolio Manager within the Neuroscience and Mental Health team at the Wellcome Trust. Georgina has been at Wellcome since 2016 where she oversees the cellular and molecular neuroscience portfolio. In addition to managing a diverse research portfolio she develops and implements strategic initiatives and builds relationships with stakeholders within the global neuroscience and mental health community. Georgina has a strong interest in translating promising research to the clinic and was previously on secondment to Wellcome Innovations. A biochemist and neuroscientist by training, Georgina is a graduate of the University of Bath and earned her MRes and PhD from Imperial College London. She completed postdoctoral training at Tufts University in Boston, Massachusetts followed by a second postdoctoral position within Industry.

Andrew Welchman, Head of Neuroscience and Mental Health, Wellcome Trust & Professor of Neural Intelligence, University of Cambridge

Andrew Welchman is Head of Neuroscience and Mental Health at the Wellcome Trust and Professor of Neural Intelligence at the University of Cambridge. He is an internationally recognised authority in the use of brain imaging and AI to understand the computations and functions of the human brain. He directs Wellcome’s funding strategy for a broad £500M portfolio in brain sciences, and recently won support for a new £200M investment in mental health. He is a Trustee of The India Alliance, and an advisor to Children In Need’s A Million and Me initiative focused on young people’s mental health.

*Participation in this activity by these individuals does not necessarily represent the official viewpoint of the U.S. Department of Health and Human Services.